RT @GavinGiovannoni: #Alemtuzumab is a reasonable rescue therapy in a cohort of 50 German RRMSers with breakthrough disease on #Fingolimod.…
Alemtuzumab vs fingolimod in #multiplesclerosis: a multi-center observational study. https://t.co/54U9mwLrp9 https://t.co/ROuQrI8VjO https://t.co/ifhiLkH5Xr
RT @GavinGiovannoni: #Alemtuzumab is a reasonable rescue therapy in a cohort of 50 German RRMSers with breakthrough disease on #Fingolimod.…
RT @OhioHealthMS: "Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod:…
#Alemtuzumab is a reasonable rescue therapy in a cohort of 50 German RRMSers with breakthrough disease on #Fingolimod. However, one patient suffered combined lethal necrotizing leukoencephalopathy and hemolytic anemia. #Alemtuzumab has risks. #NeuroSpeak h
RT @OhioHealthMS: "Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod:…
RT @OhioHealthMS: "Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod:…
RT @OhioHealthMS: "Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod:…
RT @OhioHealthMS: "Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod:…
RT @OhioHealthMS: "Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod:…
RT @OhioHealthMS: "Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod:…
"Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study" https://t.co/JDpTgXyXal
Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting #MS patients with breakthrough disease on fingolimod: a multi-center observational study https://t.co/GIgyKiOxqQ